CHRNG
Basic information
Region (hg38): 2:232539692-232548115
Previous symbols: [ "ACHRG" ]
Links
Phenotypes
GenCC
Source:
- autosomal recessive multiple pterygium syndrome (Definitive), mode of inheritance: AR
- transient neonatal myasthenia gravis (Strong), mode of inheritance: AR
- lethal multiple pterygium syndrome (Strong), mode of inheritance: AR
- autosomal recessive multiple pterygium syndrome (Strong), mode of inheritance: AR
- autosomal recessive multiple pterygium syndrome (Supportive), mode of inheritance: AR
- lethal multiple pterygium syndrome (Supportive), mode of inheritance: AR
- lethal multiple pterygium syndrome (Strong), mode of inheritance: AR
- CHRNG-associated hypo-akinesia disorder of prenatal onset (Definitive), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Multiple pterygium syndrome, lethal type; Escobar syndrome | AR | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Musculoskeletal | 16826520; 16826531; 22167768; 25608830 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (31 variants)
- Autosomal recessive multiple pterygium syndrome (14 variants)
- Lethal multiple pterygium syndrome (8 variants)
- Inborn genetic diseases (3 variants)
- CHRNG-related disorder (2 variants)
- Lethal multiple pterygium syndrome;Autosomal recessive multiple pterygium syndrome (2 variants)
- Abnormality of prenatal development or birth (1 variants)
- Autosomal recessive multiple pterygium syndrome;Lethal multiple pterygium syndrome (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CHRNG gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 132 | 135 | ||||
missense | 59 | 69 | ||||
nonsense | 14 | 20 | ||||
start loss | 0 | |||||
frameshift | 17 | 17 | ||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 11 | 15 | ||||
splice region | 1 | 3 | 27 | 2 | 33 | |
non coding | 18 | 102 | 25 | 145 | ||
Total | 36 | 21 | 82 | 237 | 27 |
Highest pathogenic variant AF is 0.000453
Variants in CHRNG
This is a list of pathogenic ClinVar variants found in the CHRNG region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
2-232539752-A-T | Autosomal recessive multiple pterygium syndrome • Lethal multiple pterygium syndrome | Uncertain significance (Jan 13, 2018) | ||
2-232539753-T-C | Likely benign (Mar 29, 2023) | |||
2-232539756-G-C | Likely benign (Mar 27, 2023) | |||
2-232539759-C-A | Likely benign (Nov 20, 2023) | |||
2-232539760-C-T | Autosomal recessive multiple pterygium syndrome • Arthrogryposis-like hand anomaly;Ankle flexion contracture;Scoliosis | Likely pathogenic (Oct 16, 2019) | ||
2-232539767-C-T | Inborn genetic diseases | Likely benign (Feb 26, 2024) | ||
2-232539768-G-A | Likely benign (Jan 20, 2024) | |||
2-232539771-G-A | Likely benign (Jul 24, 2023) | |||
2-232539777-C-T | Likely benign (Jan 14, 2024) | |||
2-232539780-G-A | Likely benign (Nov 27, 2023) | |||
2-232539803-G-A | Likely pathogenic (-) | |||
2-232539807-G-A | Autosomal recessive multiple pterygium syndrome | Pathogenic (Jun 15, 2023) | ||
2-232539809-C-G | Likely benign (Dec 13, 2023) | |||
2-232539814-A-G | Likely benign (Jul 31, 2023) | |||
2-232539815-G-A | Likely benign (Apr 17, 2023) | |||
2-232539880-G-C | Benign (Oct 02, 2019) | |||
2-232539972-C-G | Likely benign (Jul 31, 2023) | |||
2-232539976-C-T | Benign (Feb 01, 2024) | |||
2-232539977-G-A | Likely benign (Dec 20, 2023) | |||
2-232539979-C-T | Likely benign (Sep 24, 2023) | |||
2-232539983-C-G | Likely benign (Jun 07, 2023) | |||
2-232539990-A-G | Autosomal recessive multiple pterygium syndrome | Pathogenic (Jun 15, 2023) | ||
2-232539991-G-A | Pathogenic (Dec 09, 2023) | |||
2-232539993-G-C | Autosomal recessive multiple pterygium syndrome • Lethal multiple pterygium syndrome • CHRNG-related disorder | Conflicting classifications of pathogenicity (Jan 24, 2024) | ||
2-232539998-A-G | Inborn genetic diseases | Uncertain significance (Sep 17, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CHRNG | protein_coding | protein_coding | ENST00000389494 | 12 | 6677 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.33e-19 | 0.00462 | 125488 | 0 | 260 | 125748 | 0.00103 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.118 | 310 | 304 | 1.02 | 0.0000209 | 3325 |
Missense in Polyphen | 110 | 121.31 | 0.9068 | 1437 | ||
Synonymous | 0.0280 | 135 | 135 | 0.997 | 0.00000963 | 1101 |
Loss of Function | 0.177 | 29 | 30.0 | 0.965 | 0.00000187 | 275 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00204 | 0.00204 |
Ashkenazi Jewish | 0.000199 | 0.000198 |
East Asian | 0.000870 | 0.000870 |
Finnish | 0.000786 | 0.000786 |
European (Non-Finnish) | 0.00120 | 0.00119 |
Middle Eastern | 0.000870 | 0.000870 |
South Asian | 0.00121 | 0.00105 |
Other | 0.00147 | 0.00147 |
dbNSFP
Source:
- Function
- FUNCTION: After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.;
- Disease
- DISEASE: Multiple pterygium syndrome, lethal type (LMPS) [MIM:253290]: Multiple pterygia are found infrequently in children with arthrogryposis and in fetuses with fetal akinesia syndrome. In lethal multiple pterygium syndrome there is intrauterine growth retardation, multiple pterygia, and flexion contractures causing severe arthrogryposis and fetal akinesia. Subcutaneous edema can be severe, causing fetal hydrops with cystic hygroma and lung hypoplasia. Oligohydramnios and facial anomalies are frequent. {ECO:0000269|PubMed:16826520, ECO:0000269|PubMed:16826531}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Multiple pterygium syndrome, Escobar variant (EVMPS) [MIM:265000]: Non-lethal form of arthrogryposis multiplex congenita. It is an autosomal recessive condition characterized by excessive webbing (pterygia), congenital contractures (arthrogryposis), and scoliosis. Variable other features include intrauterine death, congenital respiratory distress, short stature, faciocranial dysmorphism, ptosis, low-set ears, arachnodactyly and cryptorchism in males. Congenital contractures are common and may be caused by reduced fetal movements at sensitive times of development. Possible causes of decreased fetal mobility include space constraints such as oligohydramnion, drugs, metabolic conditions or neuromuscular disorders including myasthenia gravis. {ECO:0000269|PubMed:16826520, ECO:0000269|PubMed:16826531}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Neuroactive ligand-receptor interaction - Homo sapiens (human);Highly sodium permeable acetylcholine nicotinic receptors;Neuronal System;role of nicotinic acetylcholine receptors in the regulation of apoptosis;Neurotransmitter receptors and postsynaptic signal transmission;Transmission across Chemical Synapses;Presynaptic nicotinic acetylcholine receptors;Postsynaptic nicotinic acetylcholine receptors;Activation of Nicotinic Acetylcholine Receptors;Acetylcholine binding and downstream events
(Consensus)
Recessive Scores
- pRec
- 0.0850
Intolerance Scores
- loftool
- 0.308
- rvis_EVS
- -0.42
- rvis_percentile_EVS
- 25.79
Haploinsufficiency Scores
- pHI
- 0.0665
- hipred
- N
- hipred_score
- 0.251
- ghis
- 0.505
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.616
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Chrng
- Phenotype
- muscle phenotype; homeostasis/metabolism phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); respiratory system phenotype; embryo phenotype; pigmentation phenotype;
Gene ontology
- Biological process
- muscle contraction;signal transduction;chemical synaptic transmission;synaptic transmission, cholinergic;neuromuscular synaptic transmission;ion transmembrane transport;response to nicotine;regulation of membrane potential;nervous system process;excitatory postsynaptic potential
- Cellular component
- plasma membrane;integral component of plasma membrane;acetylcholine-gated channel complex;cell junction;neuron projection;synapse;postsynaptic membrane
- Molecular function
- extracellular ligand-gated ion channel activity;protein binding;channel activity;acetylcholine receptor activity;acetylcholine-gated cation-selective channel activity;acetylcholine binding